Escolar Documentos
Profissional Documentos
Cultura Documentos
pyogenes, is the most common cause of bacterial pharyngitis in children and adolescents.
The clinical features and diagnosis of GAS pharyngitis in children and adolescents will be
discussed here. The treatment, prevention, and complications of GAS pharyngitis and the
evaluation of acute pharyngitis in children and adults are discussed separately.
In temperate climates, the incidence of GAS pharyngitis peaks during the winter and early
spring [5]. During these seasons, as many as 35 to 40 percent of cases of pharyngitis in
children and adolescents are caused by GAS.
GAS pharyngitis is most common in school-age children but may occur in younger
children, especially if they have contact with school-age children [5,6]. In a meta-analysis,
the pooled prevalence of GAS among children (<18 years) who presented to an outpatient
clinic or emergency department with sore throat was 37 percent (95% CI 32-43 percent)
[7]. The prevalence among children <5 years was 24 percent (95% CI 21-26 percent).
CLINICAL FEATURES
Children ≥3 years — In children ≥3 years, GAS pharyngitis typically has an abrupt onset.
Fever, headache, abdominal pain, nausea, and vomiting may accompany the sore throat,
which can lead to poor oral intake [3,8,9]. Additional features may include exudative
tonsillopharyngitis, with enlarged erythematous tonsils, enlarged tender anterior cervical
lymph nodes, palatal petechiae, inflamed uvula, and scarlatiniform rash (erythematous,
finely papular rash which characteristically starts in the groin and axilla and then spreads
to the trunk and extremities, followed by desquamation) (picture 1A-B) [3,8,10]. Symptoms
usually resolve spontaneously in three to five days. (See "Complications of streptococcal
tonsillopharyngitis", section on 'Scarlet fever'.)
Children <3 years — Symptoms of streptococcal infections usually are atypical in children
<3 years of age [17]. Instead of a well-defined episode of pharyngitis, they may have
protracted symptoms of nasal congestion and discharge, low-grade fever (eg, <38.3°C
[101°F]), and tender anterior cervical adenopathy [18]. This GAS symptom complex is
called "streptococcosis."
Infants <1 year of age may present with fussiness, decreased appetite, and low-grade
fever. They often have older siblings or day care contacts with GAS infection.
DIAGNOSIS
However, between 5 and 21 percent of children between 3 and 15 years of age are
pharyngeal carriers of GAS [7,19,20]. Neither throat culture nor RADT for GAS can
differentiate patients with acute GAS pharyngitis from GAS carriage with intercurrent viral
illness [3]. Such patients may fail to respond to appropriate therapy for GAS infection.
(See "Treatment and prevention of streptococcal tonsillopharyngitis", section on
'Carriers' and "Antibiotic failure in the treatment of streptococcal tonsillopharyngitis",
section on 'Streptococcal carriage'.)
Whom to test — We suggest microbiologic testing for GAS in children and adolescents
with [3,8,21]:
Whom not to test — We recommend not performing microbiologic testing for GAS in
children and adolescents with manifestations suggestive of viral illness (eg, coryza,
conjunctivitis, cough, hoarseness, anterior stomatitis, discrete ulcerative lesions or
vesicles, diarrhea) [3,21,24]. (See 'Viral infections' below.)
For children and adolescents in whom microbiologic testing for GAS is necessary:
●If throat culture results will be available in ≤48 hours, we suggest standard throat
culture rather than RADT. We verify a telephone number and obtain a pharmacy
phone number/contact information at the initial encounter.
Although we prefer throat culture, RADT is an alternative to throat culture for children
with a streptococcal score of ≥5 (ie, those in whom a positive result is most likely)
[12,25]; the streptococcal score gives one point for each of the following [12]:
•Age (5 to 15 years)
•Season (late fall, winter, early spring)
•Evidence of acute pharyngitis (erythema, edema, and/or exudates) on physical
examination
•Tender, enlarged (>1 cm) anterior cervical lymph nodes
•Middle-grade fever (between 38.3 and 39.4°C [101 and 103ºF])
•Absence of usual signs and symptoms associated with viral upper respiratory
tract infections
●If throat culture results will take >48 hours or the patient/family does not have
reliable telephone follow-up, we suggest RADT rather than throat culture.
The strategy of initial testing with throat culture is more cost effective than initial testing
with RADT. Most children who require microbiologic testing for pharyngitis do not have
GAS pharyngitis and will have a negative RADT. Given that negative RADT in children and
adolescents must be confirmed with throat culture, if RADT is used as the initial test, the
majority of children and adolescents who are tested will require both RADT and throat
culture. Limiting RADT to children in whom it is likely to be positive and performing throat
cultures in the remainder minimizes the number of children who require both tests [25].
Microbiologic tests
Throat culture — Throat culture is the reference standard for the diagnosis of acute
pharyngitis due to GAS [8,32]. When performed properly, the sensitivity of throat culture is
90 to 95 percent for GAS [3,21,33]. (See 'Specimen collection and processing' above.)
Throat culture is usually performed on 5 percent sheep blood agar [32]. After incubation for
18 to 24 hours at 35 to 37ºC, the plate is inspected for a small gray colony that gives rise
to an area of beta hemolysis. If no beta hemolytic colonies are seen after 18 to 24 hours,
the plate should be reincubated for an additional 24 hours before being interpreted as
negative [3,34]. Twenty-five to 40 percent of throat cultures that are ultimately positive for
GAS become positive after 24 hours [35].
Throat culture also can identify other bacteria that cause pharyngitis less commonly than
GAS (eg, group C and group G streptococci, Arcanobacterium haemolyticum). However,
most laboratories do not routinely identify these pathogens in throat cultures unless
specifically requested to do so.
RADT for GAS — RADT for GAS, sometimes referred to as rapid streptococcal antigen
tests (RSAT), are based upon enzyme or acid extraction of antigen from throat swabs [36-
39]. RADT results are available at the point of care in the office or emergency department
and, if positive, permit early institution of therapy for GAS pharyngitis. Early institution of
therapy enables earlier resolution of symptoms and return to school. However, early
therapy also predisposes to more frequent recurrences of GAS within 30 days [40,41].
RADT have a specificity of ≥95 percent and a sensitivity that varies between 70 and 90
percent for GAS [3,33,36-39,42-47]. In a 2016 meta-analysis of studies in which 58,244
children underwent both RADT and throat culture, the pooled sensitivity and specificity of
RADT were 85.6 percent (95% CI 83.3-87.6) and 95.4 percent (95% CI 94.5-96.2),
respectively [47]. Given the high specificity and limited sensitivity of the available tests, a
positive RADT is useful in establishing the diagnosis of GAS pharyngitis, but a negative
RADT does not rule out GAS; back-up throat culture should be performed in children and
adolescents with a negative RADT [3,21,26,27].
Molecular assays — We do not routinely use molecular assays (ie, nucleic acid
amplification tests [NAAT], polymerase chain reaction assays [PCR]) for the evaluation of
GAS pharyngitis. Additional evaluation is necessary to confirm the sensitivity and
specificity results in initial studies.
NAAT are used extensively for the diagnosis of infectious diseases [48]. Although they are
highly sensitive for GAS [49], the complexity of these tests frequently requires
performance in a laboratory setting, which increases the turn-around time for results.
However, two PCR assays for GAS pharyngitis that can be performed at the point of care
and provide results in ≤15 minutes are now available (Cobas Strep A test of the Liat
system, Alere i strep A test) [50,51]. Initial evaluation suggests that these PCR assays
have sensitivity and specificity >98 percent [51], thereby potentially eliminating the need
for follow-up throat culture in children with negative PCR results. Additional evaluation is
necessary before these tests are routinely recommended.
GAS serology — Serologic testing for GAS may be necessary to confirm previous
infection in patients who are being evaluated for acute rheumatic fever or
poststreptococcal glomerulonephritis, but it is not helpful in managing patients at the time
of clinical presentation with pharyngitis.
Other bacterial infections — Other bacterial causes of pharyngitis that may require
treatment include:
Viral infections — Viruses are the most common cause of acute pharyngitis (table 1)
[32,64,65]. Clinical features suggestive of viral etiology include concurrent conjunctivitis,
coryza, cough, hoarseness, anterior stomatitis, discrete ulcerative lesions, viral
exanthems, and/or diarrhea [3].
Viral infections in the differential diagnosis of GAS pharyngitis in children and adolescents
that have important management or infection control implications include:
Here are the patient education articles that are relevant to this topic. We encourage you to
print or e-mail these topics to your patients. (You can also locate patient education articles
on a variety of subjects by searching on "patient info" and the keyword[s] of interest.)
TRATAMIENTO
The efficacy of penicillin for primary prevention of ARF was established in the early 1950s
when military recruits with GAS tonsillopharyngitis received injectable penicillin G mixed in
peanut oil or sesame oil with 2% aluminum monostearate [12,13]. GAS eradication and
ARF primary prevention were optimized with injection schedules that provided at least 9 to
11 days of penicillin.
Subsequently, evaluation of GAS tonsillopharyngitis therapies has been based upon GAS
eradication from the upper respiratory tract; it is assumed that such eradication is an
adequate surrogate marker for efficacy in primary prevention of rheumatic fever. Antibiotic
therapy can be helpful for prevention of rheumatic fever if initiated up to nine days
following onset of symptoms [12].
Reducing transmission — The rate of GAS transmission from an infectious case to close
contacts (such as a family or school setting) is approximately 35 percent. Antibiotic
treatment does have a role for preventing transmission of GAS. In one study including 47
children with pharyngitis and positive throat culture for GAS, subsequent throat culture
after 24 hours of treatment with penicillin was negative in about 80 percent of cases [14].
In another study including 111 children with positive rapid antigen detection test (RADT)
treated with amoxicillin (50 mg/kg) by 5:00 pm on day 1, negative follow-up RADT the
following morning was observed in 91 percent of patients [15].
Data on the duration of contagion for alternative antibiotics are not available. In untreated
patients, GAS is eliminated from the upper respiratory tract by host immune factors in 50
percent of cases at one month following acute infection [16].
Additional issues related to antibiotic therapy for reducing transmission are discussed
further below. (See 'Follow-up' below.)
In the natural history of GAS pharyngitis, the incubation period is two to four days. Fever
and constitutional symptoms usually resolve within three to four days, even in the absence
of antimicrobial therapy [16]. Clinical improvement has been observed up to 48 hours
sooner in patients receiving penicillin versus placebo within the first two days of illness [5-
9].
Treatment is warranted for patients with negative rapid antigen detection testing but
subsequent positive culture results whose symptoms are resolving, in order to reduce the
likelihood of transmission.
There is some concern that early therapy may suppress host antibody response and
thereby increase risk for recurrent pharyngitis. In a study of 142 children with presumed
GAS pharyngitis, those treated with penicillin at the initial office visit had a higher incidence
of recurrent infection than those for whom treatment was delayed at least 48 hours
(recurrent infection occurred eight times more frequently) [6].
Intramuscular penicillin is the only therapy that has been shown to prevent initial attacks of
rheumatic fever in controlled studies [13,21]. These studies were performed with penicillin
G procaine in oil containing aluminum monostearate; this preparation has since been
supplanted by penicillin G benzathine. There are data suggesting that penicillin G
benzathine is effective for primary prevention of rheumatic fever, although they are not
definitive [22]. Other antimicrobials have been shown to effectively eradicate GAS from the
upper respiratory tract, and it is assumed that such eradication is a surrogate for efficacy in
primary prevention of rheumatic fever.
Resistance — Antimicrobial resistance has not been a significant issue in the treatment of
GAS. No clinical isolate of GAS has demonstrated penicillin resistance, likely due to the
organism's lack of altered penicillin-binding proteins and/or inefficient gene transfer
mechanisms for resistance [23,24]. However, streptococcal strains tolerant to penicillin
(eg, strains inhibited but not killed by penicillin in vitro, with ratio of minimum bactericidal
concentration to minimum inhibitory concentration [MIC] of ≥32) have been described [25-
28]. The clinical significance of such strains is not clear; they have been isolated in the
setting of outbreaks in which penicillin treatment failure was observed, but there was no
difference in failure rates among tolerant and susceptible strains. (See "Antibiotic failure in
the treatment of streptococcal tonsillopharyngitis".)
There have been reports of relatively high levels of resistance to macrolide antibiotics in
some regions of the United States and Asia; given the increasing use of macrolides for
treatment of upper and lower respiratory tract infections, clinicians should be cognizant of
local patterns of antimicrobial resistance [29-39].
Selection — Oral penicillin V is the agent of choice for treatment of GAS pharyngitis given
its proven efficacy, safety, narrow spectrum, and low cost [2,40-44]. The appropriate
duration is 10 days of therapy; dosing is outlined in the Table (table 3). This approach is
extrapolated from studies performed in the 1950s demonstrating that treatment of
streptococcal pharyngitis with intramuscular penicillin prevents acute rheumatic fever
[13,21]. (See "Acute rheumatic fever: Treatment and prevention".)
Amoxicillin is often used in place of oral penicillin in children, since the taste of the
amoxicillin suspension is more palatable than that of penicillin. Some data suggest that
oral amoxicillin may be marginally superior to penicillin, most likely due to better
gastrointestinal (GI) absorption [45,46]. In addition, amoxicillin has activity against one-
third of the common pathogens that cause otitis media (which presents concurrently with
GAS tonsillopharyngitis in up to 15 percent of children, particularly those under four years
of age). Dosing is outlined in the Table (table 3). (See "Acute otitis media in children:
Treatment", section on 'Initial antimicrobial therapy'.)
Cephalosporins are acceptable alternatives in patients with recurrent GAS infection but are
not recommended as first-line therapy in national guidelines [47-54]. Cephalosporins have
demonstrated better microbiologic and clinical cure rates than penicillin; these differences
appear to be greater among children than adults, and some favor use of first-generation
cephalosporins as first-line therapy in this group [55-57]. However, second- and third-
generation cephalosporins may facilitate development of antibiotic resistance and are not
favored as first-line therapy [48,49]. (See 'Recurrent infection' below.)
Antibiotic therapy directed against beta-lactamase–producing upper respiratory tract flora
(such as amoxicillin-clavulanate) remains controversial and is not indicated in patients with
acute pharyngitis, although it would be effective [2,58,59].
There are a number of acceptable dosing regimens for azithromycin (table 3); these
include the following:
●Five-day course
•12 mg/kg (not to exceed 500 mg) on day 1, followed by 6 mg/kg (not to exceed
250 mg) on days 2 through 5 [36,43,63]
•12 mg/kg (not to exceed 500 mg) on days 1 through 5 [2,64,66]
●Three-day course: 20 mg/kg (not to exceed 500 mg) on days 1 through 3 [37,65,66]
Data from studies in adults form the basis for the five-day course of 12 mg/kg on day 1
followed by 6 mg/kg on days 2 through 5; data from studies in children form the basis for
the five-day course of 12 mg/kg and the three-day course of 20 mg/kg.
For the rare patient with an erythromycin-resistant strain of GAS who is unable to tolerate
beta-lactam agents, clindamycin is an appropriate choice [29,33,67]. (See "Allergy
evaluation for immediate penicillin allergy: Skin test-based diagnostic strategies and cross-
reactivity with other beta-lactam antibiotics".)
Attempts to treat GAS pharyngitis with a single daily dose of penicillin have been
unsuccessful. Although some data suggest that once-daily amoxicillin may be sufficient for
treatment of GAS pharyngitis, others have shown that this approach is not adequate for
effective eradication; further investigation is needed [83-86]. Among the alternative
agents, azithromycin and some cephalosporins
(including cefixime, cefpodoxime, cefadroxil, and cefdinir) are effective for eradication of
pharyngeal streptococci with once-daily dosing [75,87-90].
In general, test of cure is not necessary for asymptomatic patients or their close contacts
following completion of a course of antimicrobial therapy. The majority of patients with
GAS remaining in their upper respiratory tracts after completing a course of antimicrobial
therapy are asymptomatic Streptococcus carriers [96,97].
However, follow-up test of cure is appropriate testing for asymptomatic index patients and
their asymptomatic household contacts in the following circumstances:
Recurrent infection — In the setting of recurrent acute pharyngitis with positive repeat
diagnostic testing, there are several possible explanations [96,98,99]:
In the setting of a second episode of acute pharyngitis with positive repeat diagnostic
testing, a repeat course of treatment is appropriate (table 3). Repeat treatment should be
administered with an agent with greater beta-lactamase stability than the previous agent
[58].
It is not necessary to perform follow-up testing after the second course of therapy unless
the patient remains or becomes symptomatic or unless special circumstances as outlined
above are present. (See 'Antibiotics for group A Streptococcus' above and 'Follow-
up' above.)
In the setting of multiple recurrent episodes, it may be difficult to distinguish true GAS
pharyngitis from viral pharyngitis in the setting of streptococcal carriage. It is likely that
most of these patients are carriers experiencing nonstreptococcal infections. This may be
discernible by evaluating for the presence of GAS during asymptomatic intervals and/or by
typing streptococcal isolates obtained during distinct episodes (with the expertise of a
specialized laboratory). In these circumstances, treatment with clindamycin or amoxicillin-
clavulanate may be beneficial since these agents have demonstrated high eradication
rates for pharyngeal streptococci carriage (table 3) [58,67,100]. (See 'Carriers' below.)
For patients with as many as six GAS infections in a single year or three to four episodes
in two consecutive years, tonsillectomy may be an appropriate therapeutic consideration
[101,102]. This was illustrated in a randomized trial including 187 children with recurrent
pharyngitis, of whom 95 were managed with tonsillectomy [101]. The incidence of
pharyngitis during the first two years of follow-up was significantly lower among the
tonsillectomy group. (See "Tonsillectomy and/or adenoidectomy in children: Indications
and contraindications", section on 'Recurrent throat infection'.)
PREVENTION
Carriers — In general, group A Streptococcus (GAS) resides in the oropharynx
of Streptococcus carriers in the absence of host immunologic response to the organism
[103]. In temperate climates during the winter and spring, up to 20 percent of
asymptomatic school-aged children may be carriers. About 25 percent of asymptomatic
individuals in the households of index patients harbor GAS in their upper respiratory tracts
[98]. Streptococcal carriage may persist for many months. (See "Antibiotic failure in the
treatment of streptococcal tonsillopharyngitis", section on 'Streptococcal carriage'.)
Carriers may demonstrate evidence of GAS in the upper respiratory tract during an
episode of viral pharyngitis, suggesting acute streptococcal pharyngitis. In these
circumstances, clinically distinguishing viral from streptococcal pharyngitis can be difficult.
Useful clues may include patient age, season, local epidemiology, and the nature of
presenting signs and symptoms. In addition, pharyngeal strep carriers tend to have low
antistreptolysin O (ASO) titers; they may be just above detectable. (See "Evaluation of
acute pharyngitis in adults".)
Streptococcus carriers are unlikely to spread the organism to close contacts and are at
very low risk for developing suppurative complications or acute rheumatic fever [103].
Moreover, eradication of GAS from the upper respiratory tract of carriers is much more
difficult than eradication of GAS from patients with acute infection [52,96,104]. In general,
except for the circumstances described above, Streptococcus carriers do not require
antimicrobial therapy. (See 'Follow-up' above.)
Vaccination — There is no vaccine against GAS available for clinical use, although
development of this preventive measure is under investigation [113,114]. An important
area of uncertainty is whether vaccine-induced antibodies may cross-react with host tissue
to produce nonsuppurative sequelae in the absence of clinical infection.